ClinicalTrials.gg
RecruitingNCT07689188ARQ-MA-000260Updated Oct 13, 2026

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

A Phase 2 interventional study of Roflumilast 0.3% topical foam in Hidradenitis Suppurativa (HS), sponsored by Harrison Dermatology. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Harrison Dermatology · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 13, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 162 studies in Hidradenitis Suppurativa with a site in United States — 39 open to participants now, 56 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Planned enrollment
113th of 139
10 · median 45
Started
2026
with 17 others
Phase 2
61 of 162
11 open now
Primary completion
2028-03
later than 39 of 55 live
Registered
152nd of 162
by date

Among the 162 studies in Hidradenitis Suppurativa with a site in United States, this one is the 113th largest by planned enrollment of the 139 interventional ones that give a count, is one of 18 that started in 2026, is one of 61 in phase 2, reaches primary completion later than 39 of the 55 other live ones, and was the 152nd registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

39 of the 162 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Read the detailed description

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that causes painful and inflamed lumps and abscesses often in the underarms, groin and buttocks. The purpose of this study is to assess the safety and efficacy of QD 0.3% topical roflumilast foam in patients with HS over 16 weeks, with or without previous treatment. The drug involved in this study, 0.3% topical roflumilast foam, is investigational.

03

Conditions studied

  • Hidradenitis Suppurativa (HS)

Keywords

  • HS
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 12 years or older at time of consent (or assent).
  • Participants and/or legal guardians are legally competent to sign and give or assent (for adolescents).
  • Diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 3 months.
  • Diagnosis of HS (Hurley Stage I or II) with a total abscess and inflammatory nodule (AN) count of at least 4 to ≤10, with no draining tunnels at screening and baseline visits, affecting at least one distinct anatomical region.
  • Agreement to NOT use topical and systemic antibiotics and intralesional for treatment of HS during the study.
  • Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study.
  • Subjects who have had surgery in the treatment area must be at least 3 months post-procedure (applies to deroofing/marsupialization or excision, not incision and drainage).
  • Females of must have a negative urine pregnancy test at Screening and Baseline/Day 1 and agree to use at least one highly effective or barrier method of throughout the study.

Females of non-childbearing potential must be premenarchal, (≥12 months spontaneous amenorrhea), or surgically sterile.

-In good health as judged by the Investigator based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)/legal guardian(s) must be reliable and capable of adhering to the protocol and visit schedule.

Exclusion criteria

Exclusion Criteria:

  • Medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
  • Inability to discontinue prohibited medications or treatments before Baseline or during the study.
  • Presence of draining tunnels at Screening or Baseline.
  • Unwillingness to refrain from prolonged sun exposure or tanning beds/other artificial light-emitting devices for 4 weeks before Baseline and during the study.
  • Skin conditions other than HS that could interfere with evaluation of study medication.
  • Conditions in the treatment area that could confound efficacy measurements.
  • Known allergy to in roflumilast foam.
  • Use of oral roflumilast (Daxas® or Daliresp®) within 4 weeks before Baseline.
  • History of severe depression, suicidal ideation, or suicidal behavior at Screening/Baseline.
  • Pregnant, planning pregnancy during the study, or breastfeeding.
  • Previous treatment with roflumilast cream or foam or current roflumilast use for another indication expected to continue during the study.
  • Major surgery within 4 weeks before Baseline or planned during the study.
  • History of chronic alcohol or drug abuse within 6 months before Screening.
  • History of cancer within 5 years, except fully treated basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix.
  • Parent(s)/legal guardian(s) or subjects unable to communicate, read, or understand the local language, or otherwise unsuitable for participation in the Investigator's opinion.
  • Family members of the clinical study site, study staff, sponsor, or family members of enrolled subjects living in the same household.
  • Known or suspected severe renal insufficiency or moderate to severe liver impairment ( B or C).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Roflumilast Foam 0.3

    Experimental: Roflumilast 0.3% topical foam Roflumilast 0.3% topical foam to be applied QD to all active fields for the duration of the 16-week trial. Interventions: Drug: Roflumilast 0.3% topical foam

    Drug: Roflumilast 0.3% topical foam

Interventions

  • DrugRoflumilastStudies of RoflumilastRoflumilast pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Roflumilast 0.3% topical foam applied once daily (QD) to all active hidradenitis suppurativa lesions for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16

    Mean change from baseline in the total abscess and inflammatory nodule (AN) count. AN count is the total number of abscesses and inflammatory nodules assessed at baseline and week 16.

    Time frame: Baseline and Week 16

07

Study locations

1 of 1 sites recruiting
  • Harrison Institute for Clinical Research at Harrison Dermatology
    Missouri City, Texas 77459, United States
    Recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 55 phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's planned 18 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 8, 2026
StartActual
Sep 10, 2026was Aug 2026
Primary completionEst.
Mar 10, 2028
CompletionEst.
Dec 10, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Harrison Institute for Clinical Research at Harrison Dermatology · Missouri City, United States
Show 1 removed
  • Harrison Dermatology · Missouri City, United States
Oct 13, 2026
Start date
Aug 10, 2026→Sep 10, 2026 (actual)
Oct 13, 2026
Contact
Study contact changed: h•••@harrisonderm.com · •••3990→h•••@harrisonderm.com · •••3990; a•••@harrisonderm.com · •••3990→r•••@harrisonderm.com · •••3990. See the current contact
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Harrison Institute for Clinical Research at Harrison Dermatology · Missouri City, United States
    Show 1 removed
    • Harrison Dermatology · Missouri City, United States
    Start date Aug 10, 2026→Sep 10, 2026 (now actual)
    Contact Study contact changed: h•••@harrisonderm.com · •••3990→h•••@harrisonderm.com · •••3990; a•••@harrisonderm.com · •••3990→r•••@harrisonderm.com · •••3990. See the current contact
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07689188
Lead sponsor
Harrison Dermatology
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Sep 10, 2026
Primary completion
Mar 10, 2028 (estimated)
Completion
Dec 10, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Harrison P Nguyen, MD, MBA, MPH, FAAD, DTM&H
Contact
harrison.nguyen@harrisonderm.com
346.771.3990
Research Manager
Contact
research@harrisonderm.com
346.771.3990
Harrison P Nguyen, MD, MBA, MPH, FAAD, DTM&H
principal investigator · Harrison Dermatology | Harrison Institute for Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion